CCXI
NASDAQChurchill Capital Corp XI
IPO2026
Price$13.72-0.38 (-2.66%)
01:30 PM07:45 PM
News · 26 weeks32+117%
2026-01-252026-07-19
Mix2190d
- SEC Filings15(71%)
- Offering4(19%)
- Other2(10%)
Latest news
25 items- SECSEC Form 425 filed by Churchill Capital Corp XI425 - Churchill Capital Corp XI (0002074973) (Subject)
- PRAgility Robotics Strengthens Executive Leadership Team with Appointment of Michael Beer as Chief Financial OfficerExperienced public company finance executive joins Agility as company expands commercial momentum and prepares to become the first publicly listed U.S. pure-play humanoid robotics company.SALEM, Ore., July 23, 2026 /PRNewswire/ -- Agility Robotics, a leading humanoid robotics and Physical AI company, today announced the appointment of Michael Beer as Chief Financial Officer as the company continues to strengthen its executive leadership team ahead of its planned public listing through its previously announced business combination with Churchill Capital Corp XI (NASDAQ:CCXI). As part of this planned evolution of the leadership t
- SECSEC Form 425 filed by Churchill Capital Corp XI425 - Churchill Capital Corp XI (0002074973) (Subject)
- PRAgility Opens New Fremont Facility to Accelerate Physical AI DevelopmentBay Area facility will advance the AI technologies that enable its humanoid robot, Digit, to learn new skills, supporting expanded capabilities across commercial deployments.FREMONT, Calif., July 16, 2026 /PRNewswire/ -- Agility, a leading humanoid robotics and Physical AI company, today announced the opening of its new Fremont, California, facility designed to accelerate Physical AI developments that directly improve performance in customer operations. The new site will serve as the company's software and capabilities hub, where engineering teams will train, test and advance the AI technologies that enable Agility's humanoid, Digit, to learn new skills and perform more sophisticated tasks i
- SECSEC Form 425 filed by Churchill Capital Corp XI425 - Churchill Capital Corp XI (0002074973) (Subject)
- SECSEC Form 8-K filed by Churchill Capital Corp XI8-K - Churchill Capital Corp XI (0002074973) (Filer)
- PRAgility Robotics and Churchill Capital Corp XI Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business CombinationTransaction Expected to Create The Only Publicly Listed Pure-Play Humanoid Company with Proven, Active Commercial Deployments Agility Robotics, Inc. ("Agility" or the "Company") creator of the general-purpose humanoid robot Digit, and Churchill Capital Corp XI (NASDAQ:CCXI) ("CCXI" or "Churchill XI"), a special purpose acquisition company, today announced the confidential submission of a draft registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC"). The submission of the Registration Statement marks an important milestone toward the completion of the previously disclosed proposed business combination between Agility and
- SECSEC Form 425 filed by Churchill Capital Corp XI425 - Churchill Capital Corp XI (0002074973) (Subject)
- SECSEC Form 425 filed by Churchill Capital Corp XI425 - Churchill Capital Corp XI (0002074973) (Subject)
- SECSEC Form 425 filed by Churchill Capital Corp XI425 - Churchill Capital Corp XI (0002074973) (Subject)
- SECSEC Form 425 filed by Churchill Capital Corp XI425 - Churchill Capital Corp XI (0002074973) (Subject)
- SECChurchill Capital Corp XI filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - Churchill Capital Corp XI (0002074973) (Filer)
- SECSEC Form SCHEDULE 13G filed by Churchill Capital Corp XISCHEDULE 13G - Churchill Capital Corp XI (0002074973) (Subject)
- SECSEC Form 425 filed by Churchill Capital Corp XI425 - Churchill Capital Corp XI (0002074973) (Subject)
- SECSEC Form 425 filed by Churchill Capital Corp XI425 - Churchill Capital Corp XI (0002074973) (Subject)
- SECSEC Form 425 filed by Churchill Capital Corp XI425 - Churchill Capital Corp XI (0002074973) (Subject)
- SECSEC Form 425 filed by Churchill Capital Corp XI425 - Churchill Capital Corp XI (0002074973) (Subject)
- SECChurchill Capital Corp XI filed SEC Form 8-K: Regulation FD Disclosure8-K - Churchill Capital Corp XI (0002074973) (Filer)
- PRAgility Robotics to Go Public Through $2.5 Billion Merger with Churchill Capital Corp XITransaction expected to create the only U.S. publicly listed pure-play humanoid company with proven, active commercial deployments Operating today in commercial environments with leading enterprises including Schaeffler, GXO, Toyota Motor Manufacturing Canada. Supported by leading strategic investors and partners across the AI, technology, VC, and industrial ecosystem, including DCVC, NVIDIA, Amazon, SoftBank Vision Fund 2, Foxconn, Schaeffler, Abico, and Playground Global. Digit v5 is designed to be the world’s first AI-enabled cooperatively safe humanoid robot; Agility’s vertically integrated platform is general-purpose and built for scaled deployment. Strong commercial moment
- SECSEC Form 10-Q filed by Churchill Capital Corp XI10-Q - Churchill Capital Corp XI (0002074973) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Churchill Capital Corp XISCHEDULE 13G/A - Churchill Capital Corp XI (0002074973) (Subject)
- SECSEC Form 10-K filed by Churchill Capital Corp XI10-K - Churchill Capital Corp XI (0002074973) (Filer)
- INSIDERSEC Form 3 filed by new insider Lapping Paul3 - Churchill Capital Corp XI (0002074973) (Issuer)
- INSIDERSEC Form 3 filed by new insider Murphy Stephen Anthony3 - Churchill Capital Corp XI (0002074973) (Issuer)
- SECChurchill Capital Corp XI filed SEC Form 8-K: Financial Statements and Exhibits8-K - Churchill Capital Corp XI (0002074973) (Filer)
CCXI FAQ
5 questionsWhat does Churchill Capital Corp XI do?
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an...Where does CCXI stock trade?
Churchill Capital Corp XI (CCXI) is listed on NASDAQ.When did Churchill Capital Corp XI go public?
Churchill Capital Corp XI (CCXI) completed its IPO in 2026.What are analysts saying about CCXI?
Churchill Capital Corp XI has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2022-08-04. Recent price targets range from $3100.00 to $3800.00.How can I track CCXI on Quantisnow?
Quantisnow aggregates Churchill Capital Corp XI's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CCXI to receive live email and push alerts on every new disclosure.